Table of Contents
Chapter 1 Overview of Pulmonary Drug Delivery Systems
    1.1 Definition of Pulmonary Drug Delivery Systems in This Report
    1.2 Commercial Types of Pulmonary Drug Delivery Systems
        1.2.1 Nebulizers 
        1.2.2 Dry Powder Inhaler (DPI) 
        1.2.3 Metered Dose Inhaler (MDI)
    1.3 Downstream Application of Pulmonary Drug Delivery Systems
        1.3.1 COPD 
        1.3.2 Asthma 
        1.3.3 Others
    1.4 Development History of Pulmonary Drug Delivery Systems
    1.5 Market Status and Trend of Pulmonary Drug Delivery Systems 2013-2023
        1.5.1 Europe Pulmonary Drug Delivery Systems Market Status and Trend 2013-2023
        1.5.2 Regional Pulmonary Drug Delivery Systems Market Status and Trend 2013-2023
Chapter 2 Europe Market Status and Forecast by Regions
    2.1 Market Status of Pulmonary Drug Delivery Systems in Europe 2013-2017
    2.2 Consumption Market of Pulmonary Drug Delivery Systems in Europe by Regions
        2.2.1 Consumption Volume of Pulmonary Drug Delivery Systems in Europe by Regions
        2.2.2 Revenue of Pulmonary Drug Delivery Systems in Europe by Regions
    2.3 Market Analysis of Pulmonary Drug Delivery Systems in Europe by Regions
        2.3.1 Market Analysis of Pulmonary Drug Delivery Systems in Germany 2013-2017
        2.3.2 Market Analysis of Pulmonary Drug Delivery Systems in United Kingdom 2013-2017
        2.3.3 Market Analysis of Pulmonary Drug Delivery Systems in France 2013-2017
        2.3.4 Market Analysis of Pulmonary Drug Delivery Systems in Italy 2013-2017
        2.3.5 Market Analysis of Pulmonary Drug Delivery Systems in Spain 2013-2017
        2.3.6 Market Analysis of Pulmonary Drug Delivery Systems in Benelux 2013-2017
        2.3.7 Market Analysis of Pulmonary Drug Delivery Systems in Russia 2013-2017
    2.4 Market Development Forecast of Pulmonary Drug Delivery Systems in Europe 2018-2023
        2.4.1 Market Development Forecast of Pulmonary Drug Delivery Systems in Europe 2018-2023
        2.4.2 Market Development Forecast of Pulmonary Drug Delivery Systems by Regions 2018-2023
Chapter 3 Europe Market Status and Forecast by Types
    3.1 Whole Europe Market Status by Types
        3.1.1 Consumption Volume of Pulmonary Drug Delivery Systems in Europe by Types
        3.1.2 Revenue of Pulmonary Drug Delivery Systems in Europe by Types
    3.2 Europe Market Status by Types in Major Countries
        3.2.1 Market Status by Types in Germany
        3.2.2 Market Status by Types in United Kingdom
        3.2.3 Market Status by Types in France
        3.2.4 Market Status by Types in Italy
        3.2.5 Market Status by Types in Spain
        3.2.6 Market Status by Types in Benelux
        3.2.7 Market Status by Types in Russia
    3.3 Market Forecast of Pulmonary Drug Delivery Systems in Europe by Types
Chapter 4 Europe Market Status and Forecast by Downstream Industry
    4.1 Demand Volume of Pulmonary Drug Delivery Systems in Europe by Downstream Industry
    4.2 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in Major Countries
        4.2.1 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in Germany
        4.2.2 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in United Kingdom
        4.2.3 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in France
        4.2.4 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in Italy
        4.2.5 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in Spain
        4.2.6 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in Benelux
        4.2.7 Demand Volume of Pulmonary Drug Delivery Systems by Downstream Industry in Russia
    4.3 Market Forecast of Pulmonary Drug Delivery Systems in Europe by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Pulmonary Drug Delivery Systems
    5.1 Europe Economy Situation and Trend Overview
    5.2 Pulmonary Drug Delivery Systems Downstream Industry Situation and Trend Overview
Chapter 6 Pulmonary Drug Delivery Systems Market Competition Status by Major Players in Europe
    6.1 Sales Volume of Pulmonary Drug Delivery Systems in Europe by Major Players
    6.2 Revenue of Pulmonary Drug Delivery Systems in Europe by Major Players
    6.3 Basic Information of Pulmonary Drug Delivery Systems by Major Players
        6.3.1 Headquarters Location and Established Time of Pulmonary Drug Delivery Systems Major Players
        6.3.2 Employees and Revenue Level of Pulmonary Drug Delivery Systems Major Players
    6.4 Market Competition News and Trend
        6.4.1 Merger, Consolidation or Acquisition News
        6.4.2 Investment or Disinvestment News
        6.4.3 New Product Development and Launch
Chapter 7 Pulmonary Drug Delivery Systems Major Manufacturers Introduction and Market Data
    7.1 3M 
        7.1.1 Company profile
        7.1.2 Representative Pulmonary Drug Delivery Systems Product
        7.1.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of 3M 
    7.2 GSK 
        7.2.1 Company profile
        7.2.2 Representative Pulmonary Drug Delivery Systems Product
        7.2.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of GSK 
    7.3 AstraZeneca 
        7.3.1 Company profile
        7.3.2 Representative Pulmonary Drug Delivery Systems Product
        7.3.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of AstraZeneca 
    7.4 Cipla 
        7.4.1 Company profile
        7.4.2 Representative Pulmonary Drug Delivery Systems Product
        7.4.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Cipla 
    7.5 Chiesi 
        7.5.1 Company profile
        7.5.2 Representative Pulmonary Drug Delivery Systems Product
        7.5.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Chiesi 
    7.6 Boehringer Ingelheim 
        7.6.1 Company profile
        7.6.2 Representative Pulmonary Drug Delivery Systems Product
        7.6.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim 
    7.7 Aptar 
        7.7.1 Company profile
        7.7.2 Representative Pulmonary Drug Delivery Systems Product
        7.7.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Aptar 
    7.8 Novartis 
        7.8.1 Company profile
        7.8.2 Representative Pulmonary Drug Delivery Systems Product
        7.8.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Novartis 
    7.9 Philips Respironics 
        7.9.1 Company profile
        7.9.2 Representative Pulmonary Drug Delivery Systems Product
        7.9.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Philips Respironics 
    7.10 Omron Healthcare 
        7.10.1 Company profile
        7.10.2 Representative Pulmonary Drug Delivery Systems Product
        7.10.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Omron Healthcare 
    7.11 PARI 
        7.11.1 Company profile
        7.11.2 Representative Pulmonary Drug Delivery Systems Product
        7.11.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of PARI 
    7.12 Skyepharma 
        7.12.1 Company profile
        7.12.2 Representative Pulmonary Drug Delivery Systems Product
        7.12.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Skyepharma 
    7.13 CareFusion 
        7.13.1 Company profile
        7.13.2 Representative Pulmonary Drug Delivery Systems Product
        7.13.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of CareFusion 
    7.14 Shanghai Huarui 
        7.14.1 Company profile
        7.14.2 Representative Pulmonary Drug Delivery Systems Product
        7.14.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Shanghai Huarui 
    7.15 Taian Character 
        7.15.1 Company profile
        7.15.2 Representative Pulmonary Drug Delivery Systems Product
        7.15.3 Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Taian Character 
    7.16 Chia Tai Tianqing
Chapter 8 Upstream and Downstream Market Analysis of Pulmonary Drug Delivery Systems
    8.1 Industry Chain of Pulmonary Drug Delivery Systems
    8.2 Upstream Market and Representative Companies Analysis
    8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Pulmonary Drug Delivery Systems
    9.1 Cost Structure Analysis of Pulmonary Drug Delivery Systems
    9.2 Raw Materials Cost Analysis of Pulmonary Drug Delivery Systems
    9.3 Labor Cost Analysis of Pulmonary Drug Delivery Systems
    9.4 Manufacturing Expenses Analysis of Pulmonary Drug Delivery Systems
Chapter 10 Marketing Status Analysis of Pulmonary Drug Delivery Systems
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Reference

Companies Included in Reports: